舌下免疫治疗对SNOT-22症状的纵向变化
本研究纳入43例经皮肤或IgE检测确认的成人过敏性鼻炎患者,评估舌下免疫治疗(SLIT)启动后1年内症状变化。结果显示SNOT-22总分在1-6个月和6-12个月分别降低12.1分(-35%)和12.5分(-36%)(p<0.01),鼻部、睡眠和功能子评分显著改善,54.3%患者在1-6个月达到MCID,RCAT评分也显著提高。
要点
- SLIT启动后1-6个月SNOT-22总分显著降低12.1分(-35%)。
- 鼻部、睡眠和功能子评分改善,耳/面部子评分无显著变化。
- 54.3%患者在1-6个月达到SNOT-22的MCID。
核心结论
- SLIT与过敏性鼻炎患者前6个月内SNOT-22和RCAT评分的症状改善相关,且改善持续至12个月。
研究设计与样本
- 纳入43例经皮肤或IgE检测确认的成人过敏性鼻炎患者,启动过敏原导向的SLIT,在基线、1-6个月和6-12个月记录SNOT-22和RCAT问卷。
- 采用重复测量方差分析和最小临床重要差异(MCID)阈值评估纵向变化,并对部分患者进行3个月时的探索性分析。
主要发现
- SNOT-22总分在1-6个月降低12.1分(-35%),6-12个月降低12.5分(-36%),均较基线p<0.01。
- 鼻部、睡眠和功能子评分均较基线显著改善,耳/面部子评分无显著改善。
- 54.3%患者在1-6个月达到SNOT-22总分的MCID。
- RCAT评分在1-6个月和6-12个月均显著改善。
- SNOT-22正常(≤8分)的患者比例从基线4.7%增至6-12个月的24.1%。
关键数值与推荐
- SNOT-22总分MCID达成率在1-6个月为54.3%。
- SNOT-22正常评分定义为≤8分,其比例从基线4.7%升至6-12个月24.1%。
临床怎么用
- SLIT可在启动后6个月内改善过敏性鼻炎患者的鼻部、睡眠和功能症状,并持续至12个月。
- 临床可参考SNOT-22和RCAT评分纵向监测SLIT疗效,关注MCID达成情况。
局限性
- 样本量较小(43例),探索性分析仅针对部分患者。
- 未报告对照组,无法排除安慰剂效应或自然病程影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite widespread use of nasal corticosteroids and oral antihistamines, many patients with allergic rhinitis (AR) have persistent nasal congestion/obstruction and rhinorrhea with associated sleep disturbance and daytime fatigue. Sublingual immunotherapy (SLIT) is associated with reducing symptom burden and medication use. This study aims to evaluate time to clinical benefit and magnitude of first-year benefit after SLIT initiation. METHODS: Adult AR patients confirmed by skin or IgE testing who initiated allergen-directed SLIT were included. Sinonasal Outcome Test-22 (SNOT-22) and Rhinitis Control Assessment Test (RCAT) surveys were recorded at baseline, 1-6, and 6-12 months after SLIT. Longitudinal changes were assessed using repeated measures analysis of variance and minimal clinically important difference (MCID) thresholds. Exploratory analysis at 3 months was performed for a subset of patients. RESULTS: A total of 43 SLIT patients (mean age 42.1 ± 12.0 years; 40% female) were included and demonstrated significant reductions in total SNOT-22 scores at 1-6 months (-12.1 points; -35%) and 6-12 months (-12.5 points; -36%) (p < 0.01 from baseline). Nasal, sleep, and function SNOT-22 subscores each improved significantly from baseline, whereas the ear/facial subscore did not. MCID for total SNOT-22 was achieved by 54.3% of patients at 1-6 months. RCAT scores improved significantly at 1-6 months and 6-12 months. The proportion of patients with normal SNOT-22 score (≤ 8) increased from 4.7% at baseline to 24.1% at 6-12 months. CONCLUSIONS: SLIT was associated with symptom improvement within the first 6 months of therapy based on SNOT-22 and RCAT scores. Symptom score improvements persisted to 12 months, and findings support evidence of early nasal, sleep, and function symptom alleviation with SLIT.
引用
- Zheng W, Chang JL, Butrymowicz A, et al. Longitudinal SNOT-22 Symptom Changes With Sublingual Immunotherapy (SLIT). Laryngoscope. 2026. PMID: 42174398. doi:10.1002/lary.70616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。